All News
Filter News
Found 331 articles
-
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
3/2/2022
Pardes Biosciences, Inc. announced the appointment of Thomas G. Wiggans as Chief Executive Officer and Chair of the Board of Directors.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
Sterile Vials Market Opportunity Assessment and Forecast up to 2031
12/29/2021
According to the report, the global sterile vials market was valued over US$ 4.6 Bn in 2020 and is projected to expand at a CAGR of ~8% from 2021 to 2031.
-
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
12/16/2021
SAB Biotherapeutics announced data demonstrating that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model.
-
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
10/4/2021
SAB Biotherapeutics today announced that the first patient has been dosed with SAB-185 in the Phase 3 ACTIV-2 COVID-19 trial.
-
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
9/24/2021
SAB Biotherapeutics announced that an independent Data Safety Monitoring Board has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3.
-
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
9/22/2021
SAB Biotherapeutics today announced that the U.S. Department of Defense (DoD) has awarded the company an additional $60.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program
-
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
9/20/2021
USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer treatments can and should be moving forward faster.
-
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
9/13/2021
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced it received the official written response from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-18001 (recombinant horsepox virus, live vaccine) as a potential SARS-CoV-2 vaccine to protect against COVID-19.
-
Former HHS Secretary Alex Azar Announced as Keynote Speaker for 2021 Society for Clinical Research Sites Global Site Solutions Summit
9/2/2021
Today the Society for Clinical Research Sites (SCRS), the global trade organization dedicated to representing the interests of clinical research sites, has announced Alex Azar, former Secretary of the U.S. Department of Health and Human Services (HHS), as the keynote speaker for its 16th Annual Global Site Solutions Summit.
-
While the speed of science is both lauded and mistrusted by near-equal parts of the population, the over 22 million Americans with cancer are now saying, “Wait, what about us?”
-
The Bay State biopharma industry continues to boom, even during the height of a global pandemic that has caused an economic downturn in other business sectors.
-
Woodcock faces heavy opposition from an evenly divided U.S. Senate, particularly from West Virginia Sen. Joe Manchin, who has been critical of the approval process for Biogen’s Aduhelm, formerly known as aducanumab.
-
Sterile Vials Market: Companies Collaborate with Highest Quality Machine Suppliers to Achieve Vial Sterility
8/11/2021
According to the report, the global sterile vials market was valued over US$ 4.6 Bn in 2020 and is projected to expand at a CAGR of ~8% from 2021 to 2031.
-
BioSpace Movers & Shakers, Aug. 6
8/6/2021
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers. -
Meissa Appoints Robert Walker, M.D., Chief Medical Officer
8/3/2021
Meissa Vaccines announced today the appointment of Robert Walker, M.D., as Chief Medical Officer.
-
Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) is facing yet another obstacle as at least six affiliates of Blue Cross Blue Shield likely won’t cover the drug.
-
Following a manufacturing mistake that left Emergent BioSolutions with a botched batch of Johnson & Johnson’s COVID-19 vaccine, Emergent is now facing a shareholder lawsuit accusing the company of insider trading.
-
CPhI report predicts ‘supercharged partnering’ in USA Pharma sector over the next 18-months
6/24/2021
Ahead of CPhI North America (August 10-12, 2021) a new report (CPhI US Pharma Market 2022 and Beyond) predicts rapid advances in therapy innovation, process technologies and macro changes will deliver a post-pandemic surge across the USA pharma industry.
-
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.